Health and Healthcare

Friday's Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

VANDA PHARMACEUTICAL [VNDA] +10.30%
EMERGENT BIOSOLUTION [EBS] +9.20%
BOSTON LIFE SCIENCES [BLSI] +8.03%
LEV PHARMACEUTICALS [LEVP.OB] +6.96%
ALFACELL CORP [ACEL] +6.37%

Diagnostic Substances

RG GLBL LIFESTYLS [RGBL.OB] +25.35%
OSTEOLOGIX INC [OLGX.OB] +7.96%
ICAGEN, INC. [ICGN] +4.84%
ASPENBIO PHARMA INC [APNB.OB] +4.59%
ISTA PHARMACTLS [ISTA] +4.23%

Drug Delivery

NOVADEL PHARMA INC [NVD] +4.84%
PENWEST PHARM CO [PPCO] +3.87%
PETMED EXPRESS INC [PETS] +3.29%
EMISPHERE TECH [EMIS] +1.82%
INSITE VISION INC [ISV] +1.35%

Drug Manufacturers

PLANET TECHS INC [PLNT.OB] +16.67%
SIGA TECH INC [SIGA] +10.26%
EXEGENICS INC [EXEG.OB] +8.70%
INYX INC [IYXI.OB] +4.99%
DUSA PHARM INC [DUSA] +4.05%

Medical Appliances & Equipment

ENDOCARE INC [ENDO.OB] +14.29%
EDAP TMS SA ADR [EDAP] +10.96%
ARRHYTHMIA RES TECH [HRT] +10.04%
THERMAGE, INC. [THRM] +6.82%
EXACTECH INC [EXAC] +6.28%

Medical Instruments & Supplies

ALPHATEC HOLDINGS [ATEC] +17.15%
NEPHROS INC. [NEP] +8.20%
LEMAITRE VASCULAR [LMAT] +6.70%
QUANTRX BIOMEDICAL [QTXB.OB] +6.43%
HEMOSENSE INC. [HEM] +6.10%

Medical Laboratories & Research

NATL DENTEX CP [NADX] +1.55%
ERESEARCHTECHNOLOG [ERES] +1.49%
PHARM PROD DEV [PPDI] +1.41%
NEOGENOMICS INC [NGNM.OB] +1.21%
QUEST DIAGNOSTC [DGX] +1.08%

http://www.biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.